Literature DB >> 11206619

Laparoscopic radical nephrectomy.

M D Dunn1, E M McDougall, R V Clayman.   

Abstract

Although open nephrectomy is the standard of care for localized renal-cell carcinoma, the significant postoperative pain and lengthy convalescence have encouraged the use of laparoscopy, which can yield similar 2- to 5-year survival rates. Either a transperitoneal or a retroperitoneal approach may be used, and sometimes, they are combined. Generally, the technique is limited to tumors <10 cm, but larger tumors can be removed. Nitrous oxide is avoided as an anesthetic agent. The dissection follows accepted oncologic principles: in situ renal dissection within Gerota's fascia, early ligation of the renal vessels, and careful removal of the specimen to prevent tumor spillage. Dissection of the hilum is facilitated by a PEER retractor and an Endoholder. On average, patients having laparoscopic radical nephrectomy return to normal activities approximately 4.5 weeks sooner than those having open surgery, a fact not taken into account in cost analyses. Laparoscopic nephrectomy may offer a special benefit in patients with known metastatic disease, as interleukin-2 administration can be started a month earlier than after open surgery. There may also be immunologic benefits of minimally invasive v open surgery. The technique and instruments continue to evolve, and cost-effectiveness should continue to improve.

Entities:  

Mesh:

Year:  2000        PMID: 11206619     DOI: 10.1089/end.2000.14.849

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  2 in total

Review 1.  Laparoscopic radical nephrectomy for advanced kidney cancer.

Authors:  Stephen E Pautler; McClellan M Walther
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 2.862

2.  Safety and oncological outcomes for large (stage ≥T2b) and locally advanced renal cell carcinoma: comparison between laparoscopic and modified hand-assisted laparoscopic radical nephrectomy.

Authors:  Xudong Guo; Hanbo Wang; Yuzhu Xiang; Xunbo Jin; Shaobo Jiang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.